Catalog No.
DHA04001
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG-nd
Clonality
Monoclonal
Target
MPIF2, Eosinophil chemotactic protein 2, Small-inducible cytokine A24, CCL24, Eotaxin-2, SCYA24, MPIF-2, Myeloid progenitor inhibitory factor 2, CK-beta-6, C-C motif chemokine 24
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
O00175
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
CM-101, CM101
Clone ID
CM101
Molecular imaging of fibrosis: recent advances and future directions, PMID: 30601139
CM101 stimulates cutaneous wound healing through an anti-angiogenic mechanism, PMID: 11824380
CM101-mediated recovery of walking ability in adult mice paralyzed by spinal cord injury, PMID: 9789063
Phase I study of the antineovascularization drug CM101, PMID: 9815693
Macrophage stimulation using a group B-streptococcus exotoxin (CM101) leads to axonal regrowth in the injured optic nerve, PMID: 15096692
Inhibition of Oncogenic Transcription Factor REL by the Natural Product Derivative Calafianin Monomer 101 Induces Proliferation Arrest and Apoptosis in Human B-Lymphoma Cell Lines, PMID: 25915462
Isolation and identification of the group B streptococcal toxin CM101 from infants with sepsis, PMID: 10969257
Soluble E-selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor-inhibiting anti-neovascularization agent, evaluated in phase I clinical trail, PMID: 9119883
Collagen-targeted molecular imaging in diffuse liver diseases, PMID: 32737546
Identification of a novel membrane protein, HP59, with therapeutic potential as a target of tumor angiogenesis, PMID: 11751519
CM101 treatment overrides tumor-induced immunoprivilege leading to apoptosis, PMID: 11059768
Islet Culture/Preservation Before Islet Transplantation, PMID: 26858905
Group B streptococcus, PMID: 10023965
Advances in functional and molecular MRI technologies in chronic liver diseases, PMID: 32585160
Extracellular virulence factors of group B Streptococci, PMID: 14977587
Acute inflammatory changes in subcutaneous microtumors in the ears of mice induced by intravenous CM101 (GBS toxin), PMID: 8781569
Functional studies on the anti-pathoangiogenic properties of CM101, PMID: 14517462
CM101, a polysaccharide antitumor agent, does not inhibit wound healing in murine models, PMID: 7538506
Metabolic engineering of the morphology of Aspergillus oryzae by altering chitin synthesis, PMID: 11916702
PSK as a chemopreventive agent, PMID: 8318880
Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI, PMID: 32611647
A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage, PMID: 32039405
Protein-bound polysaccharide-K (PSK) induces apoptosis via p38 mitogen-activated protein kinase pathway in promyelomonocytic leukemia HL-60 cells, PMID: 22753720
Dye-sensitized solar cells based on a donor-acceptor system with a pyridine cation as an electron-withdrawing anchoring group, PMID: 23081757
Anti-protein-bound polysaccharide-K monoclonal antibody binds the active structure and neutralizes direct antitumor action of the compound, PMID: 21249323
Protein-bound polysaccharide-K (PSK) induces apoptosis and inhibits proliferation of promyelomonocytic leukemia HL-60 cells, PMID: 21868514
Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis, PMID: 31129606
Protein-bound polysaccharide-K induces apoptosis via mitochondria and p38 mitogen-activated protein kinase-dependent pathways in HL-60 promyelomonocytic leukemia cells, PMID: 23604455
A review of research on the protein-bound polysaccharide (polysaccharopeptide, PSP) from the mushroom Coriolus versicolor (Basidiomycetes: Polyporaceae), PMID: 9457474
Viscoelastic properties of waxy and nonwaxy rice flours, their fat and protein-free starch, and the microstructure of their cooked kernels, PMID: 17636935
Modulation of interleukin-12 mRNA expression in leukocytes of cancer patients treated with CM101, PMID: 8958950
Clinical trials of anti-vascular agent group B Streptococcus toxin (CM101), PMID: 14517391
CM-101: Type I Collagen-targeted MR Imaging Probe for Detection of Liver Fibrosis, PMID: 29156148
A new selective medium for the culture of clostridia from human faeces, PMID: 7184767
[Development of anti tumor agents targeting angiogenesis], PMID: 9030228
Improved recovery of myelosuppression following chemotherapy in mice by combined administration of PSK and various cytokines, PMID: 7532894
Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy, PMID: 12168863
Protective effect of Group B Streptococcus type-III polysaccharide conjugates against maternal colonization, ascending infection and neonatal transmission in rodent models, PMID: 29416049
A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design, PMID: 22101769
Antibodies to type III group B streptococcal polysaccharide in breast milk, PMID: 15602200
[Effect of PSK on recurrence of stage II/III gastric cancer], PMID: 21224540
Characterization of polysaccharide conformational epitopes by surface plasmon resonance, PMID: 14579587
Isolation of carbohydrate-specific CD4(+) T cell clones from mice after stimulation by two model glycoconjugate vaccines, PMID: 23196974
Angiogenesis research enjoys growth spurt in the 1990s, PMID: 8637041
Construction of designer glycoconjugate vaccines with size-specific oligosaccharide antigens and site-controlled coupling, PMID: 12559788
Potentiation of virulence by group B streptococcal polysaccharides, PMID: 6376652
Group B streptococcal type II and III conjugate vaccines: physicochemical properties that influence immunogenicity, PMID: 16893995
Impaired antibody response to group B streptococcal type III capsular polysaccharide in C3- and complement receptor 2-deficient mice, PMID: 12496386
Definition of a bacterial virulence factor: sialylation of the group B streptococcal capsule, PMID: 2554337
Type III group B streptococcal polysaccharide induces antibodies that cross-react with Streptococcus pneumoniae type 14, PMID: 11895934
For research use only. Not for human or drug use.
